Advertisement

Drugs

, Volume 16, Issue 1, pp 25–45 | Cite as

Drug-Induced Liver Disease

  • Hyman J. Zimmerman
Review Article

Summary

The large number of chemical agents administered for therapeutic or diagnostic purposes can produce various types of hepatic injury by several mechanisms. Acute injury may be cytotoxic, cholestatic or mixed. Cytotoxic injury may consist of necrosis or steatosis. Cholestatic injury may be cholangiolitic (hepatocanalicular) or bland (canalicular). Chronic hepatic lesions caused by medicinal agents include chronic active hepatitis, steatosis, cirrhosis, fibrosis, hepatoportal sclerosis (non-cirrhotic portal hypertension), hepatic vein thrombosis, peliosis hepatis, adenoma, carcinoma, and angiosarcoma. There is a useful relationship between the type of hepatic injury and the chemical setting in which the drugs are employed.

Some agents produce the liver damage because they are intrinsic (true, predictable) hepatotoxins. Others (non-predictable ‘hepatotoxins’), produce hepatic injury only in the rare and unusually susceptible individual (idiosyncratic injury). Hepatotoxic agents can be recognised by their dose-dependent and experimental reproducibility, properties which are not shared by agents which produce hepatic injury only in idiosyncratic hosts.

Intrinsic hepatotoxins may be categorised as direct or indirect. Direct hepatotoxins injure the hepatocyte by direct physiochemical alteration and as a consequence produce metabolic defects. Indirect hepatotoxins selectively block metabolic pathways and, by producing a precise biochemical lesion, lead to structural changes. They may lead to hepatic steatosis or necrosis (cytotoxic indirect hepatotoxins) or block bile flow (cholestatic indirect hepatotoxins). Direct hepatotoxins are rarely encountered as drugs.

Overdoses of some drugs and antineoplastic agents appear to be indirect cytotoxic hepatotoxins, and the C-17 alkylated anabolic and contraceptive steroids are indirect, cholestatic hepatotoxins. Idiosyncracy of the host is the mechanism for most types of drug-induced hepatic injury. It may reflect allergy to the drug or a metabolic aberration of the host permitting the production of hepatotoxic metabolites.

Keywords

Halothane Hepatic Injury Phenylbutazone Contraceptive Steroid Iproniazid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adlercreutz, H. and Tenhunen, R.: Some aspects of the interaction between natural and synthetic female sex hormones and the liver. American Journal of Medicine 49: 630 (1970).PubMedGoogle Scholar
  2. Alpers, D.H. and Isselbacher, K.J.: Fatty liver: Biochemical and clinical aspects; in Schiff (Ed) Diseases of the Liver, 4th ed, pp.815–832 (Lippincott, Philadelphia 1975).Google Scholar
  3. Baghesi, S.A. and Byer, J.L.: Peliosis hepatis associated with androgenic-anabolic steroid therapy: A severe form of hepatic injury. Annals of Internal Medicine 81: 610 (1974).Google Scholar
  4. Baker, R.D. and Handler, P.: Animal experiments with tannic acid suggested by the tannic acid treatment of burns. Annals of Surgery 118: 417 (1943).PubMedGoogle Scholar
  5. Batlifora, H.A.: Thorotrast and the tumors of the liver; in Okuda and Peters (Eds) Hepatocellular Carcinoma pp.83–93 (Wiley, New York 1976).Google Scholar
  6. Bjornboe, M.; Iverson, O. and Olsen, S.: Infective hepatitis and toxic jaundice in a municipal hospital during a 5-year period. Acta Medica Scandinavica 182: 491 (1967).Google Scholar
  7. Black, M.; Mitchell, J.R.; Zimmerman, H.J. et al.: Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69: 289 (1975).PubMedGoogle Scholar
  8. Bloodworth, J.M.B. Jr.: Morphologic changes associated with sulfonylurea therapy. Metabolism 12: 287 (1963).PubMedGoogle Scholar
  9. Bottinger, L.E.; Dalen, E. and Hallin, U.: Halothane-induced liver damage: An analysis of the material reported to the Swedish Adverse Drug Reaction Committee, 1966–1973. Acta Anaesthesiologica Scandinavica 20: 40 (1976).Google Scholar
  10. Boyer, T.D.; Sun, N. and Reynolds, T.B.: Allopurinol hypersensitivity and liver damage. Western Journal of Medicine 126: 143 (1977).PubMedGoogle Scholar
  11. Brodsky, I.; Johnson, H.; Killman, S.A. et al.: Fibrosis of central and hepatic veins and perisinusoidal spaces of the liver following prolonged administration of urethane. American Journal of Medicine 30: 976 (1961).Google Scholar
  12. Burl-Andreassen, P.; Lyngbye, J. and Trolle, E.: Abnormalities in liver function during long-term diphenylhydantoin therapy in epileptic outpatients. Acta Medica Scandinavica 194: 261 (1973).Google Scholar
  13. Butler, R.C.; Shah, S.M.; Gurnow, W.A. et al.: Massive hepatic necrosis in a patient receiving allopurinol. Journal of the American Medical Association 237: 473 (1977).PubMedGoogle Scholar
  14. Clark, R.; Boriakchanyavat, V.; Davidson, A.R. et al.: Hepatic damage and death from overdose of paracetamol. Lancet 1: 66 (1973).PubMedGoogle Scholar
  15. Cohn, H.O.: Clinical studies with new rifamycin derivative. Journal of Clinical Pharmacology and Journal of New Drugs 9: 48 (1969).Google Scholar
  16. Cuthbert, M.B.: Adverse reactions to non-steroidal anti-inflammatory drugs. Current Medical Research and Opinion 2: 12 (1974).Google Scholar
  17. Dahl, M.G.C.; Gregory, M.M. and Scheuer, P.J.: Liver damage due to methotrexate in patients with psoriasis. British Medical Journal 1: 625 (1971).PubMedGoogle Scholar
  18. Dahl, M.G.C.; Gregory, M.M. and Scheuer, P.J.: Methotrexate hepatotoxicity in psoriasis — Comparison of different dose regimen. British Medical Journal 1: 654 (1972).PubMedGoogle Scholar
  19. Davis, J.: Liver damage due to tetracycline and its relationship to pregnancy; in Meyler and Peck (Eds) Drug-Induced Diseases, pp. 103–110 (Excerpta Medica, Amsterdam 1968).Google Scholar
  20. Davies, G.E. and Holmes, J.E.: Drug-induced immunological effects on the liver. British Journal of Anesthesiology 44: 941 (1972).Google Scholar
  21. Delage, C. and Lagace, R.: La peliose hepatique: Role etiologique possible des medicaments. L’Union Medicale de Canada 102: 1888 (1973).Google Scholar
  22. Despopoulus, A.: Hepatic and renal excretory metabolism of bile salts: A background for understanding steroid-induced cholestasis. Journal of Pharmacology and Experimental Therapeutics 176: 273 (1971).Google Scholar
  23. Ebert, M.H. and Shader, R.I.: Hepatic effects; in Shader and DiMascio (Eds) Psychotropic Drug Side Effects: Clinical and Theoretical Considerations, pp. 175–197 (Williams and Wilkins, Baltimore 1970).Google Scholar
  24. Edmondson, H.A.; Henderson, B. and Benton, B.: Liver-cell adenomas associated with use of oral contraceptives. New England Journal of Medicine 294: 470 (1976).PubMedGoogle Scholar
  25. Edmondson, H.A.; Reynolds, T.B.; Henderson, B. et al.: Regression of liver cell adenomas associated with oral contraceptives. Annals of Internal Medicine 86: 180 (1977).PubMedGoogle Scholar
  26. Eisen, H.J. and Ginsberg, A.L.: Disulfiram hepatotoxicity. Annals of Internal Medicine 83: 673–674 (1975).PubMedGoogle Scholar
  27. Esperitu, C.R.; Alain, J.; Glueckauf, L.G. et al.: Allopurincl-induced granulomatous hepatitis. American Journal of Digestive Diseases 21: 804 (1976).Google Scholar
  28. Farber, E.: On the pathogenesis of experimental hepatocellular carcinoma; in Okuda and Peters (Eds) Hepatocellular Carcinoma, pp. 3–24 (Wiley, New York 1976).Google Scholar
  29. Farrell, C.G.; Joshua, D.E.; Uren, R.F. et al.: Androgen-induced hepatoma. Lancet 1: 685 (1975).Google Scholar
  30. Farrell, G.C.; Joshua, D.E.; Uren, R.F.; Baird, P.J.; Perkins, K.W. and Kronenberg, H.: Androgen-induced hepatoma. Lancet 1: 685 (1975).Google Scholar
  31. Fox, K.A. and Lachen, R.B.: Liver cell adenomas and peliosis hepatitis in mice associated with oxazepam. Research Communications, Chemical Pathology and Pharmacology 8: 481 (1974).Google Scholar
  32. French, A.J.: Hypersensitivity in pathogenesis of the histopathologic changes associated with sulfonamide chemotherapy. American Journal of Pathology 22: 679 (1946).Google Scholar
  33. Garibaldi, R.A.; Drusin, R.E.; Ferebee, S.H. et al.: Isoniazid-associated hepatitis: Report of an outbreak. American Review of Respiratory Disease 106: 357 (1972).PubMedGoogle Scholar
  34. Goldstein, G.: Sarcoid reaction associated with phenylbutazone sensitivity. Annals of Internal Medicine 59: 97 (1963).PubMedGoogle Scholar
  35. Goldstein, L.I.; Ishak, K.G. and Burns, W.: Toxic hepatitis, secondary to chronic nitrofurantoin therapy. American Journal of Digestive Diseases 19: 987 (1974).PubMedGoogle Scholar
  36. Goldstein, G.B.; Lam, K.C. and Mistiiis, S.P.: Drug-induced active chronic hepatitis. American Journal of Digestive Diseases 18: 177 (1973).PubMedGoogle Scholar
  37. Griner, P.F.; El-Badawi, A. and Parkman, H.: Veno-occlusive disease after chemotherapy for acute leukemia. Annals of Internal Medicine 85: 573 (1976).Google Scholar
  38. Gross, M.A.; Speen, R.J. and Hill, J.M.: Hepatic lipidosis associated with L-asparaginase treatment. Proceedings of the Society for Experimental Biology and Medicine 130: 733 (1967).Google Scholar
  39. Gumucio, J.J. and Valdivieso, V.D.: Studies on the mechanism of the ethynylestradiol impairment of bile flow and bile salt excretion in the rat. Gastroenterology 61: 339 (1971).PubMedGoogle Scholar
  40. Hardin, B.L. Jr.: Carbon tetrachloride poisoning — A review. Industrial Medicine and Surgery 23: 93 (1954).PubMedGoogle Scholar
  41. Hargreaves, T. and Lathe, G.H.: Inhibitory aspects of bile secretion. Nature 200: 1172 (1963).PubMedGoogle Scholar
  42. Heath, C.W. Jr. and Falk, H.: Characteristics of cases of angiosarcoma of the liver among vinyl chloride workers in the United States. Annals of the New York Academy of Science 246: 231 (1975).Google Scholar
  43. Himsworth, H.P.: Lectures on the liver and its diseases (Harvard University Press, Cambridge, Massachusetts 1947).Google Scholar
  44. Hoekenga, M.T.; Bunde, C.A.; Cho, Y.W. et al.: Double-blind multicenter evaluation of a new anti-anginal drug: Perihexilene Maleate. Clinical Pharmacology and Therapeutics 13: 140 (1972).Google Scholar
  45. Hoyumpa, A.M.; Green, H.L.; Dunn, G.D. et al.: Fatty liver: Biochemical and clinical considerations. American Journal of Digestive Diseases 20: 1142 (1975).PubMedGoogle Scholar
  46. Hueper, W.E.: Cinchophen (Atophan): A critical review. Medicine 27: 43 (1948).PubMedGoogle Scholar
  47. Hurst, P. and Paget, G.E.: Protophorphyrine, cirrhosis and hepatomata in livers of mice given griseofulvin. British Journal of Dermatology 75: 105 (1963).Google Scholar
  48. Inman, W.H.W. and Mushin, W.M.: Jaundice after repeated exposure to halothane: An analysis of reports of the Committee on Safety of Medicine. British Medical Journal 1: 5010 (1974).Google Scholar
  49. Ishak, K.G.: Tumors of the liver associated with anabolic and contraceptive steroids; in Ligeman and D’Aguanno (Eds) Carcinogenesis of Some Hormonally Active Compounds (Springer-Verlag, Berlin In press 1978).Google Scholar
  50. Ishak, K.G. and Irey, W.S.: Hepatic injury associated with the phenothiazines: Clinicopathologic and follow-up studies of 36 patients. Archives of Pathology 93: 283 (1972).PubMedGoogle Scholar
  51. Ishak, K.G.; Kirschner, J.P. and Dhar, J.K.: Granulomas and cholestatic hepatocellular injury associated with phenylbutazone. Report of two cases. American Journal of Digestive Diseases 22: 611 (1977).PubMedGoogle Scholar
  52. Ishak, K.G. and Rabin, L.: Benign tumors of the liver. Medical Clinics of North America 59: 995 (1975).PubMedGoogle Scholar
  53. Iuel, A.J.: Didsfeld ved guldenhandking i. Denmark 1960–1969. Ugeskr. Laeger 135: 1639 (1973).PubMedGoogle Scholar
  54. Jalota, R. and Freston, J.A.: Severe intrahepatic cholestasis due to thiabendazole. American Journal of Tropical Medicine 23: 676 (1974).Google Scholar
  55. Joshi, P.H. and Conn, H.O.: The syndrome of methoxyflurane-associated hepatitis. Annals of Internal Medicine 80: 395 (1974).PubMedGoogle Scholar
  56. King, J.A. and Blount, R.E.: An unexpected reaction to procainamide. Journal of the American Medical Association 186: 603 (1963).PubMedGoogle Scholar
  57. Klatskin, G.: Toxic and drug-induced hepatitis; in Schiff (Ed) Diseases of the Liver, 4th ed, pp.604–710 (Lippincott, Philadelphia 1975).Google Scholar
  58. Klatskin, G.: Hepatic tumors: Possible relationship to use of oral contraceptives. Gastroenterology 73: 386 (1977).PubMedGoogle Scholar
  59. Klatskin, G. and Smith, D.P.: Halothane induced hepatitis; in Gerohand Sickinger (Eds) Drugs and the Liver, pp.289–296 (Schattauer-Verlag, Stuttgart 1975).Google Scholar
  60. Klemola, H.; Pentilla, O.; Runeberg, L. et al.: Anicteric liver damage during nitrofurantoin medication. Scandinavian Journal of Gastroenterology 10: 501 (1975).PubMedGoogle Scholar
  61. Koch, M.J.; Seeff, L.B.; Crumley, CE. et al.: Quinidine-toxicity: A report of a case and a review of the literature. Gastroenterology 70: 1136 (1976).PubMedGoogle Scholar
  62. Koff, R.S.; Gardner, R.; Harinasuta, U. et al.: Profile of hyperbilirubinemia in three hospital populations. Clinical Research 18: 680 (1970).Google Scholar
  63. Lieber, C.S.: Alcohol and the liver. Transition from adaption to tissue injury; in Khuana, Israel and Kalant (Eds) Alcoholic Liver Pathology, pp.171–189 (Addiction Research Foundation, Ontario 1975).Google Scholar
  64. Little, D.M.: Effects of halothane on liver function; in Greene (Ed) Clinical Anesthesia: Halothane, pp.85–137 (Davis, Philadelphia 1968).Google Scholar
  65. Little, D.M. and Whetstone, H.J.: Anesthesia and the liver. Anesthesiology 25: 815 (1964).PubMedGoogle Scholar
  66. Maddrey, W.C. and Boitnott, J.K.: Isoniazid hepatitis. Annals of Internal Medicine 79: 1 (1973).PubMedGoogle Scholar
  67. Maddrey, W.C. and Boitnott, J.K.: Severe hepatitis from methyldopa. Gastroenterology 68: 351 (1975).PubMedGoogle Scholar
  68. Maddrey, W.C. and Boitnott, J.K.: Drug-induced chronic liver disease. Gastroenterology 72: 1348 (1977).PubMedGoogle Scholar
  69. Mays, E.T.; Christopherson, W.M.; Mahr, M.M.; et al.: Hepatic changes in young women ingesting contraceptive steroids. Hepatic hemorrhage and primary hepatic tumors. Journal of the American Medical Association 235: 730 (1976).PubMedGoogle Scholar
  70. McAlister, W.H.; Anderson, M.S.; Bloomberg, G.R. et al.: Lethal effects of tannic acid in the barium enema: Report of three fatalities and experimental studies. Radiology 80: 765 (1963).Google Scholar
  71. McCann, J.; Choi, E.; Yamasaki, E. et al.: Detection of carcinogens as mutagens in the Salmonella/microsome test-Assay of 300 chemicals (rapid in-vitro, screening of environmental carcinogens and mutagens). Proceedings of the National Academy of Science 72: 5135 (1975).Google Scholar
  72. Metreau, J.M.; Dhumeaux, D. and Bethelot, P.: Oral contraceptives and the liver. Digestion 7: 318 (1972).PubMedGoogle Scholar
  73. Mihas, A.A.; Holley, P.; Koff, R.S. et al.: Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil. Gastroenterology 70: 770 (1976).PubMedGoogle Scholar
  74. Miller, P.R. and Miller, J.A.: Hepatocarcinogenesis by chemicals; in Popper and Schaffner (Eds) Progress in Liver Disease, vol. V, pp.699–711 (Grune and Stratton,New York 1976).Google Scholar
  75. Mistilis, S.P.: Chronic active hepatitis; in Schiff (Ed) Diseases of the Liver 4th Ed, pp.787–814 (Lippincott, Philadelphia 1975).Google Scholar
  76. Mitchell, J.R.; Potter, W.Z.; Hinson, J.A.; Snodgrass, W.R.; Timbrell, J.A. and Gillette, J.R.: Toxic drug reactions; in Eichler et al. (Eds) Handbook of Experimental Pharmacology, New Series. Vol. XXVIII/3, pp.282–419 (Springer-Verlag, Berlin 1975).Google Scholar
  77. Mitchell, J.R.; Zimmerman, H.J.; Ishak, K.G. et al.: Isoniazid liver injury: Clinical spectrum, pathology and probable pathogenesis. Annals of Internal Medicine 84: 181 (1976).PubMedGoogle Scholar
  78. Nadel, J. and Kosek, J.: Peliosis hepatis. Twelve cases associated with oral androgen therapy. Archives of Pathology and Laboratory Medicine 101: 405 (1977).Google Scholar
  79. Parker, L.N.: Hepatitis and propylthiouracil. Annals of Internal Medicine 82: 228 (1975).PubMedGoogle Scholar
  80. Perkins, J.: Phenindione jaundice. Lancet 1: 125 (1962a).PubMedGoogle Scholar
  81. Perkins, J.: Phenindione sensitivity. Lancet 1: 127 (1962b).PubMedGoogle Scholar
  82. Peters, R.L.; Edmondson, H.A.; Mikkelsen, W.P. et al.: Tetracycline induced fatty liver in non-pregnant patients. American Journal of Surgery 113: 622 (1967).PubMedGoogle Scholar
  83. Phillips, M.J.; Oda, M.; Mak, E. et al.: Microfilament dysfunction as a possible cause of intrahepatic cholestasis. Gastroenterology 69: 48 (1975).PubMedGoogle Scholar
  84. Pietsch, J. and Meakins, J.L.: Complications of povidone-iodine absorption in topically treated burn patients. Lancet 1: 280–282 (1976).PubMedGoogle Scholar
  85. Popper, H.; Schaffner, F. and Kenk, H.: Molecular pathology of cholestasis; in Taylor (Ed) The Hepatobiliary System. Fundamental and Pathological Mechanisms, pp.605–629 (Plenum Press, New York 1976).Google Scholar
  86. Popper, H. and Thomas, L.B.: Alterations of liver and spleen among workers exposed to vinyl chloride. Annals of the New York Academy of Science 246: 172 (1975).Google Scholar
  87. Pratt, C.B. and Johnson, W.W.: Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy. Cancer 28: 361 (1971).PubMedGoogle Scholar
  88. Recknagel, R.O. and Glende, E.A. Jr.: Carbon tetrachloride hepatotoxicity: An example of lethal cleavage. CRC Critical Review of Toxicology 2: 263 (1973).Google Scholar
  89. Reed, C.B. and Cox, A.J. Jr.: The human liver after radiation injury. American Journal of Pathology 48: 597 (1965).Google Scholar
  90. Rees, L.: Drugs used in the treatment of psychiatric disorders. Abstracts of World Medicine 39: 129 (1966).Google Scholar
  91. Reynolds, T.B.: Laxative liver disease; in Gerok and Sickinger (Eds) Drugs and the Liver, pp.319–325 (Schattauer-Verlag, Stuttgart 1975).Google Scholar
  92. Rigberg, L.A.; Robinson, M.J. and Esperitu, C.: Chlorpropamide-induced granulomas. A probable hypersensitivity in liver and bone-marrow. Journal of the American Medical Association 235: 409 (1976).PubMedGoogle Scholar
  93. Rodman, J.S.; Deutsch, D.J. and Gutman, S.I.: Methyldopa hepatitis. A report of six cases in the literature. American Journal of Medicine 60: 941 (1976).PubMedGoogle Scholar
  94. Rosenblum, L.E.; Korn, R.J. and Zimmerman, H.J.: Hepatocellular jaundice as a complication of iproniazid therapy. Archives of Internal Medicine 105: 583 (1960).PubMedGoogle Scholar
  95. Rosenkrantz, H.S. and Carr, H.S.: Hydrazine antidepressants and isoniazid: Potential carcinogens. Lancet 1: 1354 (1971).Google Scholar
  96. Russell, R.I.; Allan, J.G. and Patrick, R.: Active chronic hepatitis after chlorpromazine ingestion. British Medical Journal 1: 655 (1973).PubMedGoogle Scholar
  97. Russell, R.M.O.; Bagheri, S.A. and Boyer, J.L.: The hepatic lesion of hypervitaminosis A. A unique pattern of hepatic fibrosis with portal hypertension and ascites. Gastroenterology 65: 568 (1973a).Google Scholar
  98. Schaffner, F. and Raisfield, I.H.: Drugs and the liver. A review of metabolism and adverse reactions. Advances Internal Medicine 115: 221 (1969).Google Scholar
  99. Schenker, S.; Olson, K.N.; Dunn, D. et al.: Intrahepatic cholestasis due to therapy of rheumatoid arthritis. Gastroenterology 64: 622 (1973).PubMedGoogle Scholar
  100. Schenker, S.; Breen, K.J. and Heimberg, M.: Pathogenesis of tetracycline-induced fatty liver; in Gerok and Sickinger (Eds) Drugs and the Liver, pp.269–280 (Schattauer-Verlag, Stuttgart 1975).Google Scholar
  101. Scheuer, P.J.: Chronic hepatitis. A problem for the pathologist. Histopathology 1: 5 (1977).PubMedGoogle Scholar
  102. Scheuer, P.J.: Liver Biopsy Interpretation, 2nd ed, pp.40–55 (Williams and Wilkins, Baltimore 1973).Google Scholar
  103. Schiff, L.: Personal communication (1976).Google Scholar
  104. Schweitzer, I.L. and Peters, R.L.: Acute submassive hepatic necrosis due to methyldopa: A case demonstrating possible induction of chronic liver disease. Gastroenterology 66: 1203 (1974).PubMedGoogle Scholar
  105. Seaman, W.E.; Ishak, K.G. and Plotz, P.H.: Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Annals of Internal Medicine 80: 1 (1974).PubMedGoogle Scholar
  106. Seiinger, M. and Koff, R.S.: Thorotrast and the liver: A reminder. Gastroenterology 68: 799–803 (1975).Google Scholar
  107. Sherlock, S.: Diseases of the Liver and Biliary System, 5th Ed, pp.340–382 (Blackwell, Oxford 1975a).Google Scholar
  108. Sherlock, S.: Hepatic adenomas and oral contraceptives. Gut 16: 753 (1975b).PubMedGoogle Scholar
  109. Shikata, T.; Oda, T.; Naito, C. et al.: Phospholipid fatty liver: A proposal of a new concept and its electron microscopical study. Acta Pathologica Japonica 20: 467 (1970).PubMedGoogle Scholar
  110. Simmonds, F.; Feldman, B. and Gerety, D.: Granulomatous hepatitis in a patient receiving allopurinol. Gastroenterology 62: 101 (1972).Google Scholar
  111. Stafford, A.: Drugs acting on the heart; in Meyler and Herxheimer (Eds) Side Effects of Drugs, Vol. III, pp.277–279 (Excerpta Medica, Amsterdam 1971).Google Scholar
  112. Sterup, K. and Mosbech, J.: Budd-Chiari syndrome after taking oral contraceptives. British Medical Journal 4: 660 (1967).PubMedGoogle Scholar
  113. Teller, D.N.: Phenothiazines and butyrophenones in relation to neurochemistry and pharmacology in Denbar (Ed) Psycho-pharmacological Treatment: Theory and Practice pp. 28–42 (Marcel Dekker, New York 1975).Google Scholar
  114. Thomas, F.B.: Chronic aggressive hepatitis induced by halothane. Annals of Internal Medicine 81: 487 (1974).PubMedGoogle Scholar
  115. Ticktin, H.E. and Zimmerman, H.J.: Hepatic dysfunction and jaundice in patients receiving triacetyloleandomyoin. New England Journal of Medicine 267: 964 (1962).Google Scholar
  116. Tonder, M.; Nordoy, A. and Elgio, K.: Sulfonamide-induced chronic liver disease. Scandinavian Journal of Gastroenterology 9: 23 (1974).Google Scholar
  117. Trey, C.; Lipworth, L.; Chalmers, T. et al.: Fulminant hepatic failure. Presumable contribution of halothane. New England Journal of Medicine 279: 798 (1968).PubMedGoogle Scholar
  118. Utili, R.; Boitnott, J. and Zimmerman, H.J.: Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 72: 610 (1976).Google Scholar
  119. Van Thiel, D.H.; DeBelle, R.; Mellow, M. et al.: Tolazamide hepatotoxicity. A case report. Gastroenterology 67: 506 (1974).PubMedGoogle Scholar
  120. Vester, J.W.; Sunder, J.H.; Aarons, J.H. et al.: Long-term monitoring during Clofibrate therapy. Clinical Pharmacology and Therapeutics 11: 689 (1971).Google Scholar
  121. Weir, J.F. and Comfort, M.W.: Toxic cirrhosis caused by cinchophen. Archives of Internal Medicine 28: 476 (1933).Google Scholar
  122. Wheeler, H.O.: Secretion of bile; in Schiff (Ed) Diseases of the Liver 4th Ed, pp.87–110 (Lippincott, Philadelphia 1975).Google Scholar
  123. Wildhirt, E.: Therapie chronische Leberkrankheiten Mit D-Pencillamin. Munchener Medisinische Wochenschrift 116: 217–220 (1974).Google Scholar
  124. Yanoff, M. and Rawson, A.J.: Peliosis hepatis. An anatomic study with demonstration of two varieties. Archives of Pathology 77: 159 (1964).PubMedGoogle Scholar
  125. Zimmerman, H.J.: Clinical and laboratory manifestations of hepatotoxicity. Annals of New York Academy of Science 104: 954 (1963).Google Scholar
  126. Zimmerman, H.J.: The spectrum of hepatotoxicity. Perceptives in Biology and Medicine 12: 135 (1968).Google Scholar
  127. Zimmerman, H.J.: Liver injury induced by chemicals and drugs; in Bockus (Ed) Gastroenterology, 3rd ed., Vol. III. Ch. 105, pp.299–341 (W.B. Saunders, Philadelphia 1976a).Google Scholar
  128. Zimmerman, H.J.: Experimental hepatotoxicity; in Born et al. (Eds) Handbook of Experimental Pharmacology, Vol. XVI/5, Ch. 1, pp.1–120 (Springer-Verlag, Berlin 1976b).Google Scholar

Copyright information

© ADIS Press 1978

Authors and Affiliations

  • Hyman J. Zimmerman
    • 1
  1. 1.Medical ServiceVeterans Administration Hospital and George Washington University School of MedicineWashington DCUSA

Personalised recommendations